Literature DB >> 31101590

Applications of MALDI mass spectrometry imaging for pharmacokinetic studies during drug development.

Masanobu Nishidate1, Mitsuhiro Hayashi2, Hiroaki Aikawa2, Kouji Tanaka3, Naoyuki Nakada4, Shin-Ichi Miura5, Shoraku Ryu2, Tatsuya Higashi6, Yoshinori Ikarashi7, Yasuhiro Fujiwara8, Akinobu Hamada9.   

Abstract

The concentration and distribution of a drug or its metabolites in tissues are key factors for understanding drug efficacy or toxicity. Conventional pharmacokinetic studies show that the plasma concentration of a drug is often unrelated to the intra-tissue concentration. Moreover, it is difficult to predict the distribution of a drug in tissues, particularly those with complex structures, even though the overall tissue concentration is measured by using homogenizing procedures. Mass spectrometry imaging (MSI) enables visualization of the spatial distribution and quantities of drugs in tissue sections without labeling, which can significantly impact on the development of new drugs and translational research. Recent advances in instrument technology and the knowledge accumulated to date could further improve the sensitivity, spatial resolution, and reproducibility of MSI. Here we present current applications of matrix-assisted laser desorption/ionization (MALDI)-MSI in pharmacokinetic imaging (PK-imaging) studies, give an overview of MALDI-MSI procedures, highlight the importance of internal standards, and give details of quantitative approaches. We also point out the need for standardizing MALDI-MSI techniques. PK-imaging using standardized MALDI-MSI methods, independent of instrument or technician expertise, is expected to contribute to acquiring reliable data in drug development and translational research in the future.
Copyright © 2019 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Application; Drug; LC-MS/MS; MALDI; Mass spectrometry imaging; Pharmacokinetics; Standardization; Validation

Year:  2019        PMID: 31101590     DOI: 10.1016/j.dmpk.2019.04.006

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  4 in total

1.  Comparison of Bevacizumab Quantification Results in Plasma of Non-small Cell Lung Cancer Patients Using Bioanalytical Techniques Between LC-MS/MS, ELISA, and Microfluidic-based Immunoassay.

Authors:  Noriko Iwamoto; Megumi Takanashi; Takashi Shimada; Jiichiro Sasaki; Akinobu Hamada
Journal:  AAPS J       Date:  2019-08-20       Impact factor: 4.009

2.  Mass spectrometry imaging: new eyes on natural products for drug research and development.

Authors:  Jin-Jun Hou; Zi-Jia Zhang; Wen-Yong Wu; Qing-Qing He; Teng-Qian Zhang; Ya-Wen Liu; Zhao-Jun Wang; Lei Gao; Hua-Li Long; Min Lei; Wan-Ying Wu; De-An Guo
Journal:  Acta Pharmacol Sin       Date:  2022-10-13       Impact factor: 7.169

3.  FT-ICR Mass Spectrometry Imaging at Extreme Mass Resolving Power Using a Dynamically Harmonized ICR Cell with 1ω or 2ω Detection.

Authors:  Mathieu Tiquet; Raphaël La Rocca; Stefan Kirnbauer; Samuele Zoratto; Daan Van Kruining; Loïc Quinton; Gauthier Eppe; Pilar Martinez-Martinez; Martina Marchetti-Deschmann; Edwin De Pauw; Johann Far
Journal:  Anal Chem       Date:  2022-05-23       Impact factor: 8.008

4.  Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation.

Authors:  Andrés Rubiano; Amruta Indapurkar; Ryosuke Yokosawa; Alina Miedzik; Barry Rosenzweig; Ayesha Arefin; Chloe M Moulin; Keri Dame; Neil Hartman; Donna A Volpe; Murali K Matta; David J Hughes; David G Strauss; Tomasz Kostrzewski; Alexandre J S Ribeiro
Journal:  Clin Transl Sci       Date:  2021-04-03       Impact factor: 4.689

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.